Literature DB >> 21615789

Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C.

Scott R Walter1, Hla-Hla Thein, Heather F Gidding, Janaki Amin, Matthew G Law, Jacob George, Gregory J Dore.   

Abstract

BACKGROUND AND AIM: The incidence of hepatocellular carcinoma (HCC) has increased in Australia in recent decades, a large and growing proportion of which occurs among a population chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). However, risk factors for HCC among these high-risk groups require further characterization.
METHODS: We conducted a population-based cohort study using HBV and HCV cases notified to the New South Wales Health Department between 2000 and 2007. These were linked to cause of death data, HIV/AIDS notifications, and hospital records. Proportional hazards regression was used to identify significant risk factors for developing HCC.
RESULTS: A total of 242 and 339 HCC cases were linked to HBV (n = 43 892) and HCV (n = 83 817) notifications, respectively. For both HBV and HCV groups, being male and increasing age were significantly associated with risk of HCC. Increasing comorbidity score indicated high risk, while living outside urban areas was associated with lower risk. Hazard ratios for males were two to three times those of females. For both HBV and HCV groups, cirrhosis, alcoholic liver disease, and the interaction between the two were associated with significantly and considerably elevated risk.
CONCLUSION: This large population-based study confirms known risk factors for HCC. The association with older age highlights the potential impact of HBV and HCV screening of at-risk groups and early clinical assessment. Additional research is required to evaluate the impact of improving antiviral therapy on HCC risk.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21615789     DOI: 10.1111/j.1440-1746.2011.06785.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  24 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 2.  Mechanisms of hepatocarcinogenesis in chronic hepatitis C.

Authors:  Jonathan K Mitchell; David R McGivern
Journal:  Hepat Oncol       Date:  2014-09-09

3.  The clinical significance and biological function of large tumour suppressor 2 in hepatocellular carcinoma.

Authors:  Rong Liang; Yan Lin; Chun-Ling Yuan; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Hai-Hong Ye
Journal:  Cell Prolif       Date:  2017-03-01       Impact factor: 6.831

4.  Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.

Authors:  Xianzheng Wang; Aihua Dong; Jingjing Xiao; Xingjun Zhou; Haili Mi; Hanqian Xu; Jiming Zhang; Bin Wang
Journal:  Cell Mol Immunol       Date:  2015-07-13       Impact factor: 11.530

5.  Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection.

Authors:  Mayumi Tokunaga; Hirofumi Uto; Kohei Oda; Masahito Tokunaga; Seiichi Mawatari; Kotaro Kumagai; Kouichi Haraguchi; Makoto Oketani; Akio Ido; Nobuhito Ohnou; Atae Utsunomiya; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2014-01-25       Impact factor: 7.527

6.  Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population.

Authors:  Padmini Krishnamurthy; Nyla Hazratjee; Dan Opris; Sangeeta Agrawal; Ronald Markert
Journal:  J Gastrointest Oncol       Date:  2016-06

7.  KASL clinical practice guidelines: management of alcoholic liver disease.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2013-09-30

8.  A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population.

Authors:  Yao Liu; Shandong Pan; Li Liu; Xiangjun Zhai; Jibin Liu; Juan Wen; Yixin Zhang; Jianguo Chen; Hongbing Shen; Zhibin Hu
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

9.  Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.

Authors:  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2020-11-19       Impact factor: 7.527

10.  Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma.

Authors:  Tonghai Xing; Li Huang; Zhenhai Yu; Lin Zhong; Shuyun Wang; Zhihai Peng
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.